John Renger
Chief Tech/Sci/R&D Officer bij CEREVEL THERAPEUTICS HOLDINGS, INC.
Vermogen: 269 260 $ op 31-03-2024
Profiel
Momenteel is John Renger Chief Scientific Officer van Cerevel Therapeutics Holdings, Inc. In het verleden was Dr. Renger Associate Vice President bij Merck & Co, Inc. en Vice President-Research & Development bij Imbrium Therapeutics LP. Hij behaalde een doctoraat en een bachelor diploma aan de Universiteit van Iowa.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
07-02-2024 | 6 370 ( 0.00% ) | 269 260 $ | 31-03-2024 |
Actieve functies van John Renger
Bedrijven | Functie | Begin |
---|---|---|
CEREVEL THERAPEUTICS HOLDINGS, INC. | Chief Tech/Sci/R&D Officer | 01-05-2019 |
Eerdere bekende functies van John Renger
Bedrijven | Functie | Einde |
---|---|---|
Purdue Pharma LP
Purdue Pharma LP Pharmaceuticals: MajorHealth Technology Purdue Pharma LP engages in the development and provision of prescription medicines. It offers a portfolio of medical products in categories, including prescription opioids, sleep, laxatives, antiseptics, and dietary supplement. The company was founded by Raymond R. Sackler in 1991 and is headquartered in Stamford, CT. | Corporate Officer/Principal | 01-04-2018 |
MERCK & CO., INC. | Corporate Officer/Principal | 01-08-2016 |
Imbrium Therapeutics LP
Imbrium Therapeutics LP Pharmaceuticals: MajorHealth Technology Part of Purdue Pharma LP, Imbrium Therapeutics LP is a clinical-stage biopharmaceutical company based in Stamford, CT. The private company is dedicated to advancing medical science through the development of important new pharmacologic and biologic therapeutics. Imbrium is pursuing oncology chemotherapeutics, treatments for disorders of the central nervous system, and non-opioid approaches to the management of pain. The company strives to develop and bring to market new medicines that serve the unmet needs of patients, physicians, and health systems worldwide. Imbrium has built a robust and diversified pipeline of investigational drug candidates, and actively collaborates with industry and academic partners to identify and advance future impactful medicines. | Chief Tech/Sci/R&D Officer | - |
Opleiding van John Renger
University of Iowa | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 2 |
---|---|
MERCK & CO., INC. | Health Technology |
CEREVEL THERAPEUTICS HOLDINGS, INC. | Health Technology |
Bedrijven in privébezit | 2 |
---|---|
Purdue Pharma LP
Purdue Pharma LP Pharmaceuticals: MajorHealth Technology Purdue Pharma LP engages in the development and provision of prescription medicines. It offers a portfolio of medical products in categories, including prescription opioids, sleep, laxatives, antiseptics, and dietary supplement. The company was founded by Raymond R. Sackler in 1991 and is headquartered in Stamford, CT. | Health Technology |
Imbrium Therapeutics LP
Imbrium Therapeutics LP Pharmaceuticals: MajorHealth Technology Part of Purdue Pharma LP, Imbrium Therapeutics LP is a clinical-stage biopharmaceutical company based in Stamford, CT. The private company is dedicated to advancing medical science through the development of important new pharmacologic and biologic therapeutics. Imbrium is pursuing oncology chemotherapeutics, treatments for disorders of the central nervous system, and non-opioid approaches to the management of pain. The company strives to develop and bring to market new medicines that serve the unmet needs of patients, physicians, and health systems worldwide. Imbrium has built a robust and diversified pipeline of investigational drug candidates, and actively collaborates with industry and academic partners to identify and advance future impactful medicines. | Health Technology |